Summary: The U.S. Supreme Court on Monday temporarily restored a federal rule permitting mifepristone to be prescribed through telehealth services and dispensed by mail, overturning an appellate court action that had re-imposed an older requirement for an in-person visit to receive the medication. Justice Samuel Alito issued an administrative stay that pauses the decision of the New Orleans-based 5th U.S. Circuit Court of Appeals while requests from two manufacturers are considered.
Alito, who is responsible for emergency matters from the group of states that includes Louisiana, ordered the state to file its response to the drugmakers' emergency applications by Thursday and indicated that the administrative stay would expire on May 11. The interim order is intended to preserve access to the drug by telemedicine and the mail while the legal dispute continues in the lower courts, and the Supreme Court would be expected either to extend the stay or to issue a formal ruling by the expiry date.
The 5th Circuit had moved to reinstate an older federal requirement that a clinician see a patient in person before dispensing mifepristone after hearing a challenge brought by the Republican-led state of Louisiana. The appeal court's action on May 1 effectively narrowed nationwide access to the drug before the Supreme Court's temporary intervention.
The case returns the contentious issue of abortion access to the justices, coming as Republican and Democratic political contests move toward the November U.S. congressional elections. The immediate legal posture reflects a continuing sequence of procedural and substantive challenges to federal Food and Drug Administration policies governing mifepristone.
Earlier litigation has produced notable rulings. In 2024 the Supreme Court unanimously rejected an initial attempt by anti-abortion groups and some doctors to unwind FDA regulations that had eased access to mifepristone, finding that those plaintiffs lacked legal standing to pursue their claim. The current dispute centers on a 2023 rule adopted during the Biden administration that eliminated the in-person dispensing requirement for the drug.
Mifepristone, which received FDA approval in 2000, is used together with misoprostol to carry out medication abortions. The method now comprises more than 60% of abortions in the United States, according to the information in the ongoing litigation and public reporting cited in the court proceedings. The broader legal fights over access followed the Supreme Court's 2022 ruling that overturned Roe v. Wade, a decision that has resulted in 13 states enacting near-total bans on abortion and other states imposing sharp restrictions.
Louisiana filed suit against the FDA in 2025, asserting that the 2023 measure removing the in-person dispensing rule is unlawful and conflicts with the state's near-total ban on abortion. The manufacturers of mifepristone intervened in the litigation to defend the 2023 regulation - Danco Laboratories, which supplies the branded product, and GenBioPro, which makes a generic version.
The current federal executive branch stance was also reflected in the proceedings. The Republican President's administration opposed Louisiana's challenge, citing an ongoing review of safety regulations related to mifepristone. In April, U.S. District Judge David Joseph in Lafayette, Louisiana, declined to enjoin the 2023 regulation but agreed with the administration to pause final action in the case while that federal review proceeded. The 5th Circuit then blocked the rule on May 1, prompting the interim intervention by the Supreme Court.
Note on related market commentary included in the record: The record also contains an unrelated segment describing an investment product named ProPicks AI, which claims to offer stock portfolios chosen by advanced AI and cites a flagship strategy called Tech Titans that reportedly doubled the S&P 500 within 18 months, including winners such as Super Micro Computer (+185%) and AppLovin (+157%). That segment poses the question of which stock might be the next to rise and promotes a call to "Pick Stocks with AI." The legal and regulatory developments concerning mifepristone remain separate from that market commentary.